Fluad H5N1 Pandemic Influenza Vaccine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prophylaxis of Avian Influenza Vaccine
Conditions
Prophylaxis of Avian Influenza Vaccine
Trial Timeline
May 1, 2007 → Feb 1, 2009
NCT ID
NCT00478816About Fluad H5N1 Pandemic Influenza Vaccine
Fluad H5N1 Pandemic Influenza Vaccine is a phase 2 stage product being developed by Novartis for Prophylaxis of Avian Influenza Vaccine. The current trial status is completed. This product is registered under clinical trial identifier NCT00478816. Target conditions include Prophylaxis of Avian Influenza Vaccine.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00478816 | Phase 2 | Completed |
Competing Products
20 competing products in Prophylaxis of Avian Influenza Vaccine